Sugi Predict

Sugi Predict / Compounds / SCHEMBL4580075

SCHEMBL4580075

SCHEMBL4580075

CCOC(=O)c1cnc(N2CCOCC2)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.61
▸ PIK3CA P42336 1/20 0.61
▸ L3MBTL1 Q9Y468 2/20 0.55
▸ KDM4E B2RXH2 3/20 0.55
▸ ALDH1A1 P00352 3/20 0.54
▸ LMNA P02545 3/20 0.54
▸ ALOX15 P16050 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ HPGD P15428 1/20 0.54
▸ OGA O60502 1/20 0.53
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ MAPT P10636 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ TP53 P04637 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ MC4R P32245 1/20 0.47
▸ HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1618526 0.88 L3MBTL1 (0.50) POLBPIK3CAL3MBTL1KDM4EALDH1A1
SCHEMBL12952642 0.87 POLB (0.54) POLBPIK3CAL3MBTL1ALDH1A1LMNA
SCHEMBL6984326 0.87 MAPT (0.57) POLBPIK3CAL3MBTL1ALDH1A1LMNA
SCHEMBL25678417 0.85 MAPT (0.56) POLBPIK3CAL3MBTL1ALDH1A1LMNA
SCHEMBL1011771 0.84 PIK3CA (0.48) POLBPIK3CAL3MBTL1KDM4EALDH1A1
SCHEMBL24881185 0.84 OGA (0.54) POLBPIK3CALMNAOGAMEN1
SCHEMBL15038302 0.84 HDAC3 (0.56) POLBALDH1A1LMNAOGAMEN1
SCHEMBL8196662 0.84 POLB (0.67) POLBPIK3CAALDH1A1ALOX15HSD17B10
SCHEMBL20552861 0.83 OGA (0.53) POLBPIK3CALMNAOGAMEN1
SCHEMBL8194207 0.83 OGA (0.53) POLBPIK3CAKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 — — EP claimed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 — — EP claimed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 — — WO claimed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 — — US disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 — — US disclosed
WO-2024074611-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2024-04-11 — — WO disclosed
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2024-04-09 — — US disclosed
EP-3687543-B1 COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARM INC (US) 2024-03-20 — — EP disclosed
WO-2023130070-A2 CARBOLINE COMPOUNDS AND USE THEREOF PTC THERAPEUTICS, INC. (US) 2023-07-06 — — WO disclosed
CN-111386118-B Combination pharmaceutical agents as RSV inhibitors 英安塔制药有限公司 2023-05-09 — — CN disclosed
EP-2007720-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2008-12-31 — — EP disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 — — US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 — — US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 — — US disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 — — WO disclosed
WO-2007118137-A1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2007-10-18 — — WO disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 — — EP disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 — — EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 POLB 4513/4885PIK3CA 2807/4885L3MBTL1 4773/4885
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 POLB 4513/4885PIK3CA 2807/4885L3MBTL1 4773/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 POLB 4513/4885PIK3CA 2807/4885L3MBTL1 4773/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 POLB 3210/4885PIK3CA 2314/4885L3MBTL1 4863/4885
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 POLB 488/4885PIK3CA 2549/4885L3MBTL1 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.